Recent Finacing
Recent Raise
Stablix Therapeutics develops the RESTORED platform of heterobifunctional small molecules (RESTORACS) that recruit deubiquitinases to remove ubiquitin and restore protein function for rare diseases, oncology, and immunology.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
